Evidence map›Paper›PMID 30341117›Full record

ArticleBMJ open2018

Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study.

Maki Jitsumura, Andrew Laurence Cunningham, Matthew David Hitchings, Saiful Islam, Angharad P Davies, Paula E Row, Andrew D Riddell, James Kinross, Tom S Wilkinson, G J Jenkins and 2 more

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Fecal transplantation for treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maki JitsumuraDepartment of Colorectal Surgery, Singleton Hospital, Swansea, UK.
Andrew Laurence CunninghamDepartment of Colorectal Surgery, Singleton Hospital, Swansea, UK.
Matthew David HitchingsMedical Microbiology and Infectious Diseases, Swansea University Medical School, Swansea, UK.
Saiful IslamSwansea Trial Unit, Swansea University, Swansea, UK.
Angharad P DaviesPublic Health Wales Microbiology, Singleton Hospital, Swansea University Medical School, Swansea, UK.
Paula E RowBiochemistry Group, Swansea University Medical School, Swansea, UK.
Andrew D RiddellDepartment of Colorectal Surgery, Redcliffe Hospital, Brisbane, Queensland, Australia.
James KinrossDepartment of Surgery and Cancer, St. Mary's Hospital, Imperial College London, London, UK.
Tom S WilkinsonMedical Microbiology and Infectious Diseases, Swansea University Medical School, Swansea, UK.
G J JenkinsMolecular Carcinogenesis, Institute of Life Science, Swansea University Medical School, Swansea, UK.
John G WilliamsInstitute of Life Science 2, Swansea University Medical School, Swansea, UK.
Dean Anthony HarrisDepartment of Colorectal Surgery, Singleton Hospital, Swansea, UK.ORCID 0000-0003-2673-8946

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe interaction of the gut microbiota with the human host is implicated in the pathogenesis of inflammatory and immunological diseases including ulcerative colitis (UC). Faecal microbiota transplantation (FMT) as a method of restoring gut microbial diversity is of increasing interest as a therapeutic approach in the management of UC. The current literature lacks consensus about the dose of FMT, route of administration and duration of response. METHODS AND ANALYSIS: This single-blinded randomised trial will explore the feasibility of FMT in 30 treatment-naïve patients with histologically confirmed distal UC limited to the recto-sigmoid region (up to 40 cm from the anal verge). This study aims to estimate the magnitude of treatment response to FMT under controlled conditions. The intervention (FMT) will be administered by rectal retention enema. It will test the feasibility of randomising patients to: (i) single FMT dose, (ii) five daily FMT doses or (iii) control (no FMT dose). All groups will receive standard antibiotic gut decontamination and bowel preparation before FMT. Recruitment will take place over a 24-month period with a 12-week patient follow-up. Trial objectives include evaluation of the magnitude of treatment response to FMT, investigation of the clinical value of metabolic phenotyping for predicting the clinical response to FMT and testing the recruitment rate of donors and patients for a study in FMT. This feasibility trial will enable an estimate of number of patients needed, help determine optimal study conditions and inform the choice of endpoints for a future definitive phase III study. ETHICS AND DISSEMINATION: The trial is approved by the regional ethics committee and is sponsored by Abertawe Bro Morgannwg University's Health Board. Written informed consent from all patients will be obtained. Serious adverse events will be reported to the sponsor. Trial results will be disseminated via peer review publication and shared with trial participants. TRIAL REGISTRATION NUMBER: ISRCTN 58082603; Pre-results.

Indexed as

Gastrointestinal MicrobiomeColitis, UlcerativeFeasibility StudiesFecal Microbiota TransplantationHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicRemission InductionSingle-Blind MethodTreatment Outcomefaecal microbiota transplantationfeasibility studymicrobiomequality of liferandomised trialulcerative colitis

Identifiers

PMID30341117
PMCPMC6196852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.